Invivyd's Q4 2024 Pemgarda revenue hit $13.8 million, up 48% from Q3, with $69.3 million in year-end cash reserves. Next: Access Our New, Shockingly Simple 'Alert System' The company is conducting ...
On Friday, Invivyd Inc. (NASDAQ:IVVD) announced that new in vitro neutralization data show continued neutralizing activity of Pemgarda (pemivibart) and pipeline candidate VYD2311 against dominant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback